Literature DB >> 26079596

Significantly enhanced bioavailability of niclosamide through submicron lipid emulsions with or without PEG-lipid: a comparative study.

Xingwang Zhang1, Yong Zhang, Tianpeng Zhang, Jianping Zhang, Baojian Wu.   

Abstract

Niclosamide (NL) has demonstrated its great potential in fighting against leukaemia recently. However, either oral or systemic delivery of NL is challenged by its insoluble nature. Here, we developed two different NL-loaded submicron lipid emulsions (NL-SLEs) and compared their suitability in bioavailability enhancement. Conventional and PEGylated NL-SLEs (NL-CSLEs and NL-PSLEs) were prepared by melt dispersion/high pressure homogenisation technique. They were about 307.8 and 162.2 nm in particle size, respectively, and both of them possessed satisfactory stability and drug load (>9.0%). After oral administration, significantly enhanced bioavailability was achieved through NL-CSLEs and NL-PSLEs (441.11 and 463.55% relative to the reference). Apart from global size, NL-CSLEs and NL-PSLEs exhibited similar attributes in release, lipolysis, mucin binding, etc. Taken together, SLEs with or without PEG-lipid have shown to be promising for oral delivery of NL. PEG-lipid could significantly reduce the particle size of SLEs. But, macromolecular PEG-lipid was required to effectively stealth the lipid carriers.

Entities:  

Keywords:  Bioavailability; PEGylation; lipid-based formulation; niclosamide; stealth

Mesh:

Substances:

Year:  2015        PMID: 26079596     DOI: 10.3109/02652048.2015.1057251

Source DB:  PubMed          Journal:  J Microencapsul        ISSN: 0265-2048            Impact factor:   3.142


  6 in total

1.  2-Hydroxy-N-phenylbenzamides and Their Esters Inhibit Acetylcholinesterase and Butyrylcholinesterase.

Authors:  Martin Krátký; Šárka Štěpánková; Neto-Honorius Houngbedji; Rudolf Vosátka; Katarína Vorčáková; Jarmila Vinšová
Journal:  Biomolecules       Date:  2019-11-05

2.  Amorphous Solid Dispersions and the Contribution of Nanoparticles to In Vitro Dissolution and In Vivo Testing: Niclosamide as a Case Study.

Authors:  Miguel O Jara; Zachary N Warnken; Robert O Williams
Journal:  Pharmaceutics       Date:  2021-01-14       Impact factor: 6.321

3.  NICLOSAMIDE-EXFOLIATED ANIONIC CLAY NANOHYBRID REPURPOSED AS AN ANTIVIRAL DRUG FOR TACKLING COVID-19; ORAL FORMULATION WITH TWEEN 60/EUDRAGIT S100.

Authors:  N Sanoj Rejinold; Huiyan Piao; Goeun Choi; Geun-Woo Jin; Jin-Ho Choy
Journal:  Clays Clay Miner       Date:  2021-11-11       Impact factor: 2.207

4.  Airway Delivery of Hydrogel-Encapsulated Niclosamide for the Treatment of Inflammatory Airway Disease.

Authors:  Jiraporn Ousingsawat; Raquel Centeio; Inês Cabrita; Khaoula Talbi; Oliver Zimmer; Moritz Graf; Achim Göpferich; Rainer Schreiber; Karl Kunzelmann
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

5.  Cation-π interactions drive hydrophobic self-assembly and aggregation of niclosamide in water.

Authors:  Said A H Vuai; Mtabazi G Sahini; Isaac Onoka; Lucy W Kiruri; Daniel M Shadrack
Journal:  RSC Adv       Date:  2021-10-07       Impact factor: 4.036

6.  Niclosamide Is Active In Vitro against Mycetoma Pathogens.

Authors:  Abdelhalim B Mahmoud; Shereen Abd Algaffar; Wendy van de Sande; Sami Khalid; Marcel Kaiser; Pascal Mäser
Journal:  Molecules       Date:  2021-06-30       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.